Effects of pantoprazole, a novel H+/K+‐ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole

Takeuchi, Koji; Konaka, Akira; Nishijima, M.; Kato, Shinichi; Yasuhiro, Tetsuya

doi:10.1046/j.1440-1746.1999.01843.x

Cited by 15 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical efficacy and safety studies with pantoprazole (40 mg daily) have consistently shown healing rates for oesophageal erosions of 70–80% following 4 weeks of treatment and of > 80% after 8 weeks. These rates are superior to those obtained with ranitidine, 11–13 and comparable to those for omeprazole 14–16 and lansoprazole 17 ,. 18 Clinical studies have indicated that pantoprazole is effective for the rapid healing of erosive oesophagitis, 19 as well as in relieving symptoms in patients with mild erosive disease 20 ,.…”

Section: Introductionmentioning

confidence: 51%

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Kovacs

Wilcox

DeVault

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SUMMARYBackground: Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease. Aim: To compare the efficacy and safety of pantoprazole vs. nizatidine for the treatment of symptomatic gastrooesophageal reflux disease and endoscopically documented erosive oesophagitis (grade ‡ 2). Methods: A multicentre, double-blind, randomized, active-controlled study (221 patients) was performed to compare 20 and 40 mg pantoprazole daily with nizatidine 150 mg b.d. (maximum, 8 weeks). The primary end-point was endoscopic healing of erosive oesophagitis (grade 1 or 0). The secondary end-point was symptomatic improvement. Results: Healing averaged 61%, 64% and 22% for pantoprazole 20 mg, pantoprazole 40 mg and nizatidine

show abstract

Section: Introductionmentioning

confidence: 51%

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Kovacs

Wilcox

DeVault

et al. 2002

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…It is of interest to note that the effectiveness of FEMY-R7 at 30 or 100 mg/kg was comparable to that of 30 mg/kg pantoprazole, since it is well known that proton-pump inhibitors such as pantoprazole inhibit gastric secretion [35,36], protect parietal cells [7,37,38], and suppress H. pylori growth [39,40,41]. Compared with the results using CLO kits that detect urease activity, the bacterial cells were detected in more mice (Tables 1 and 2); i.e., the partially-positive stomachs in CLO test revealed H. pylori bacteria in Giemsa-stained mucosa (Figure 3).…”

Section: Discussionmentioning

confidence: 99%

In vitroandin vivoanti-Helicobacter pyloriactivities of FEMY-R7 composed of fucoidan and evening primrose extract

Cai

Kim²,

Jang

et al. 2014

Lab Anim Res

View full text Add to dashboard Cite

Effects of FEMY-R7, composed of fucoidan and evening primrose extract, on the bacterial growth and intragastric infection of Helicobacter pylori as well as gastric secretion were investigated in comparison with a proton-pump inhibitor pantoprazole. For in vitro anti-bacterial activity test, H. pylori (1×108 CFU/mL) was incubated with a serially-diluted FEMY-R7 for 3 days. As a result, FEMY-R7 fully inhibited the bacterial growth at 100 µg/mL, which was determined to be a minimal inhibitory concentration. In addition, 6-hour incubation with H. pylori, FEMY-R7 inhibited urease activity in a concentration-dependent manner, showing a median inhibitory concentration of 1,500 µg/mL. In vivo elimination study, male C57BL/6 mice were infected with the bacteria by intragastric inoculation (5×109 CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10, 30 or 100 mg/kg FEMY-R7 for 7 days. In Campylobcter-like organism-detection test and bacterial identification, FEMY-R7 exerted a high bacteria-eliminating capacity at 30-100 mg/kg, comparably to 30 mg/kg pantoprazole. In contrast to a strong antacid activity of pantoprazole in a pylorus-ligation study, FEMY-R7 did not significantly affect gastric pH, free HCl, and total acidity, although it significantly decreased fluid volume at a low dose (10 mg/kg). The results indicate that FEMY-R7 eliminate H. pylori from gastric mucosa by directly killing the bacteria and preventing their adhesion and invasion, rather than by inhibiting gastric secretion or mucosal damage.

show abstract

“…53,[81][82][83] It should be noted that Takeuchi et al 84) reported that portal hypertension significantly inhibited epithelial cell proliferation at the ulcer margins, delaying the healing of acetic acid ulcer in rats. Nonetheless, omeprazole treatment significantly accelerated ulcer healing in both normal rats and rats with portal hypertension to a similar extent.…”

Section: Anti-secretory Drugs H2-blockersmentioning

confidence: 99%

An Overview of Acetic Acid Ulcer Models —The History and State of the Art of Peptic Ulcer Research—

Okabe

Amagase

2005

Biological & Pharmaceutical Bulletin

207

166

View full text Add to dashboard Cite

Four types of experimental chronic ulcer models, named acetic acid ulcer models, have been developed to examine the healing process of peptic ulcers, screen anti-ulcer drugs, and better evaluate the adverse effects of various anti-inflammatory drugs on the gastrointestinal mucosa. The model easily and reliably produces round, deep ulcers in the stomach and duodenum, allowing acetic acid ulcer production in mice, rats, Mongolian gerbils, guinea pigs, cats, dogs, miniature pigs, and monkeys. These ulcer models highly resemble human ulcers in terms of both pathological features and healing process. The models have been established over the past 35 years and are now used throughout the world by basic and clinical scientists. One of the characteristic features of acetic acid ulcers in rats is the spontaneous relapse of healed ulcers Ͼ100 d after ulceration, an endoscopically confirmed phenomenon. Indomethacin significantly delays the healing of acetic acid ulcers, probably by reducing endogenous prostaglandins and inhibiting angiogenesis in ulcerated tissue. Helicobacter pylori significantly delays healing of acetic acid ulcers and causes relapse of healed ulcers at a high incidence in Mongolian gerbils. Anti-secretory drugs (e.g. omeprazole), prostaglandin analogs, mucosal defense agents (e.g. sucralfate), and various growth factors all significantly enhance healing of acetic acid ulcers. Gene therapy with epidermal growth factor and vascular endothelial growth factor applied to the base of acetic acid ulcers in rats is effective in enhancing ulcer healing. Since an inhibitor of nitric oxide syntase prevents ulcer healing, nitric oxide might be involved in the mechanism underlying ulcer healing. We conclude that acetic acid ulcer models are quite useful for various studies related to peptic ulcers.

show abstract

Effects of pantoprazole, a novel H⁺/K⁺‐ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole

Cited by 15 publications

References 23 publications

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

In vitroandin vivoanti-Helicobacter pyloriactivities of FEMY-R7 composed of fucoidan and evening primrose extract

An Overview of Acetic Acid Ulcer Models<br>—The History and State of the Art of Peptic Ulcer Research—

Contact Info

Product

Resources

About

Effects of pantoprazole, a novel H+/K+‐ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole

Cited by 15 publications

References 23 publications

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active‐controlled, double‐blind study

In vitroandin vivoanti-Helicobacter pyloriactivities of FEMY-R7 composed of fucoidan and evening primrose extract

An Overview of Acetic Acid Ulcer Models<br>&mdash;The History and State of the Art of Peptic Ulcer Research&mdash;

Contact Info

Product

Resources

About

Effects of pantoprazole, a novel H⁺/K⁺‐ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: A comparative study with omeprazole and lansoprazole

An Overview of Acetic Acid Ulcer Models<br>—The History and State of the Art of Peptic Ulcer Research—